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Several years ago, the discovery of a highly tumorigenic subpopulation of stem-like cells embedded within
fresh surgical isolates of malignant gliomas lent support to a new paradigm in cancer biology—the cancer
stem cell hypothesis. At the same time, these ‘‘glioma stem cells’’ seemed to resolve a long-standing conun-
drum on the cell of origin for primary cancers of the brain. However, central tenets of the cancer stem cell
hypothesis have recently been challenged, and the cellular origins of stem-like cells within malignant glioma
are still contended. Here, we summarize the issues that are still in play with respect to the cancer stem cell
hypothesis, and we revisit the developmental origins of malignant glioma. Do glioma stem cells arise from
developmentally stalled neural progenitors or from dedifferentiated astrocytes? Five separate predictions
of a neural progenitor cell of origin are put to the test.Introduction
Primary tumors of the central nervous system account for less
than 1.5% of all new cancer cases reported in the United States
each year (Central Brain Tumor Registry of the United States,
http://www.CBTRUS.org). However, the majority of these can-
cers are either anaplastic astrocytomas or malignant gliomas.
The more aggressive manifestations of these cancers (WHO
grades III and IV, see Figure 1) are for all intents and purposes in-
curable. Accordingly, astrocytic tumors are the third leading
cause of cancer-related death among middle aged men and
the fourth leading cause of death for women between 15 and
34 years of age (Prados and Wilson, 1993). Pilocytic astrocyto-
mas (WHO grade I) are the most common form of brain cancer
in children (Kleihues and Cavenee, 2007). Some of these pediat-
ric tumors are surgically curable, and many of the others are re-
sponsive to radiation (Kortmann et al., 2003) or conventional
chemotherapy (Packer et al., 1997; Prados et al., 1997); how-
ever, the clinical impact of surgery, radiation, and cytotoxic
drugs on growing children can be significant.
Against this backdrop, malignant gliomas and pediatric brain
cancers have become one of the favored scientific vehicles for
‘‘the cancer stem cell hypothesis.’’ The central tenet of this hy-
pothesis is that solid and liquid tumors alike are composed of
(1) a relatively small subset of slowly cycling cells that undergo
self renewal for an indefinite/unlimited period of time and (2)
a larger population of cells that have committed to a particular
fate and have finite division capacity (Reya et al., 2001). A prac-
tical corollary of the cancer stem cell hypothesis is that cancer
therapies frequently fail because they are directed toward the
wrong cellular targets (Tan et al., 2006).
An important and testable notion with direct relevance to the
cancer stem cell hypothesis is that tumors arise from mutated,
developmentally arrested progenitor cells that normally drive or-
ganogenesis and/or tissue repair. For several reasons, cancers
of the brain lend themselves especially well to critical assess-
ment from this developmental perspective. Adult neural progen-
itors have been identified and mapped to spatially restricted832 Neuron 58, June 26, 2008 ª2008 Elsevier Inc.regions of the postnatal brain. Marker proteins and antibodies
are available for most of the specific cell types that comprise
the adult brain. Protocols for the culture of normal, multipotent
neural progenitors are well established. Above all, the ‘‘wall
charts’’ for development of the normal brain, though far from
complete, are surpassed in detail only by those for development
of blood.
Cancer stem cells have now been isolated from a wide range
of CNS neoplasms, including gliomas (both adult and pediatric)
anaplastic oligodendrogliomas, and malignant medulloblasto-
mas (Table 1). For neuro-oncologists, the notion that brain
tumors arise from developmentally arrested neural progenitors
seems to resolve some long standing puzzles: Why are these
tumors (especially high-grade gliomas) so notoriously resistant
to radiation and chemotherapy? What accounts for the bizarre
mixture of cell types found in the most aggressive gliomas
(WHO grade IV, a.k.a. glioblastoma mulitiforme; see Table 1)?
Above all, how do any cancers arise in an organ that is well iso-
lated from environmental toxins and—to a first approximation—
mitotically inert?
Despite its considerable teleological charm, the cancer stem
cell hypothesis remains a work in progress. Many aspects of
cancer biology do not lend themselves well to a stem cell per-
spective. Recent developments in the area of stem cell research
refresh a decades-long polemic on the cell of origin for malignant
gliomas. We will start this review by framing the issues that are
currently in dispute with respect to the cancer stem cell hypoth-
esis in general and glioma stem cells in the particular. We will
then critically evaluate five testable predictions of the cancer
stem cell hypothesis.
The Cancer Stem Cell Hypothesis and Astrocytic
Tumors: The Issues at Hand
One practical component of the cancer stem cell hypothesis
addresses the issue of intrinsic resistance to radiation and che-
motherapy. Cancer stem cells are predicted to be difficult tar-
gets for cancer therapeutics because (1) they cycle slowly, (2)
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Tumors
The World Health Organization (WHO) recognizes
ten major classes of neuroepithelial tumors and
more than 40 subclasses. Of these, 60% belong
to one major class—the astrocytic tumors, which
areparsed into fourgrades inaccordwithhistopath-
ological appearance and clinical prognosis. As indi-
cated, there is a direct relationship between tumor
grade and age of onset and an inverse relationship
between tumor grade and time to death. A subset
of grade IV gliomas are thought to arise via progres-
sion of diffuse astrocytomas (WHO grade II) or ana-
plastic astrocytomas (WHOgrade III). Grade IV glio-
mas that arise via progression are referred to as
‘‘secondary gliomas.’’ However, most high-grade
gliomas are diagnosed in patients with no evidence
of a pre-existing, less malignant astrocytoma and
are termed ‘‘primary gliomas.’’ See Kleihues and
Cavenee (2007) for further reading.express high levels of drug export proteins, and (3) they may not
express or may not depend upon the oncoproteins that are
targeted by the new generation of ‘‘smart drugs,’’ such as Glee-
vec and Iressa. Collectively, these observations and consider-
ations (and speculations) provide a fresh rationale for tumor re-
sistance to therapy and suggest that a new class of agents
should be designed to specifically target cancer stem cells
(Al-Hajj et al., 2004).
However, some cancers respond dramatically to chemother-
apy, including cancers that arise from germ cells (i.e., testicular
cancer) and cancers that clearly have a stem cell component,
such as chronic myelogenous leukemia (Polyak and Hahn,
2006). Acquired resistance to radiation or chemotherapy is
even more difficult to reconcile with the cancer stem cell hypoth-
esis. Selective pressure and clonal expansion of tumor cells with
preexistingmutations for drug resistanceprovides aplausible (al-
beit more prosaic) explanation for these typical failures of cancer
medicine (Weinberg, 2007). In accord with the clonal expansion
view, high-throughput DNA sequence analysis of breast cancer
stem cells (marked by the cell surface antigen CD44) shows
that the CD44-positive tumor stem cells are genetically more dis-similar to their CD44-negative counterparts than would be pre-
dicted by the cancer stem cell hypothesis (Shipitsin et al., 2007).
For brain cancers in particular, skeptics complain that glioma
stem cells are defined in operational ways that have little or no
bearing on brain development (see below). Moreover, even if
their existence is conceded, the cellular and developmental ori-
gins of ‘‘glioma stem cells’’ can be contended. Do these cells ac-
tually arise from postnatal neural progenitors? Alternatively, are
glioma stem cells the progeny of mature glia or committed glial
progenitors that have dedifferentiated to a more stem-like state?
The latter point of view, though somewhat counterintuitive, has
gained credibility with recent reports on genetic reprogramming
of adult skin cells to pluripotent embryo stem cells by transfec-
tion with small sets of transcription factors (Nakagawa et al.,
2008; Okita et al., 2007; Takahashi et al., 2007; Wernig et al.,
2007). These extreme examples of genetic reprogramming are
low-frequency events in culture. Moreover, insertional muta-
genic events may contribute to the process because retroviral
expression vectors have thus far been required to transduce
the transcription factors. Nevertheless the skin-to-stem cell
transformations do illustrate the fundamental genetic plasticityTable 1. Milestones in the History of the Glioma Stem Cell
 Mid-to-late 19th century: Lobstein, Cohnheim, and others comment on similarities between embryogenesis and the biology of cancer
cells (1).
 1926: Bailey and Cushing develop the brain tumor classification system from which modern taxonomies derive. The system emphasizes the
histological resemblance of brain tumor cells to cells of the developing CNS (2).
 Mid 60s: Metcalf, Sachs, and others develop in vitro clonogenic assays to display the cellular progenitors of blood (3 and 4).
 1966: Altman and Das describe postnatal neurogenesis in rats (5).
 1988: Weissman and coworkers isolate the multipotent hematopoietic stem cell (6).
 1992: Reynolds and Weiss identify postnatal neural progenitors (neurosphere cultures) (7).
 1994: Dick and coworkers isolate malignant stem cells from human acute myeloid leukemia (8).
 2000: Prospective isolation of human CNS stem cells (9).
 2002–2004: Cancer stem cells isolated from adult and pediatric astrocytomas (10–13).
(1) Rather (1978); (2) Bailey and Cushing (1926); (3) Bradley andMetcalf (1966); (4) Ichikawa et al. (1966); (5) Altman and Das (1966); (6) Spangrude et al.
(1988); (7) Reynolds and Weiss (1992); (8) Lapidot et al. (1994); (9) Uchida et al. (2000); (10) Ignatova et al. (2002); (11) Galli et al. (2004); (12) Hemmati
et al. (2003); (13) Singh et al. (2003).Neuron 58, June 26, 2008 ª2008 Elsevier Inc. 833
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sion of committed astrocytes or astrocyte progenitors into
multipotent neural progenitors seems to be a small and easily
surmountable challenge. Indeed, one cannot rule out that rever-
sion to a less-differentiated state might be a normal, albeit rare,
event in healthy CNS tissue.
These unresolved issues in cancer cell biology and malignant
glioma are the focus of this review. We will begin with a quick
synopsis of glioma stem cell biology and a brief overview of
the candidates for ‘‘glioma cell of origin.’’ We will then address
the cell of origin issue by considering five testable predictions
of the cancer stem cell hypothesis.
Glioma Stem Cells: Definitions
Neural stem cells are classically defined as cells active in devel-
opment, cell turnover, or repair that are (1) self-renewing and (2)
multipotent. Although the definition of ‘‘glioma stem cell’’ was ini-
tially coined to reflect these two cardinal properties, there is
growing recognition that cancer stem cells, while self-renewing,
cannot be considered multipotent because the differentiated
progeny derived from a transformed precursor are genetically
abnormal. The operational definition of glioma stem cell is a tu-
mor subpopulation that can self-renew in culture, perpetuate
a tumor in orthotopic transplant in vivo, and generate diversified
neuron-like and glia-like postmitotic progeny in vivo or in vitro.
Glioma stem cells meeting these criteria grow as neuro-
spheres in culture and can express CD133 (a.k.a. Prominin-
1)—a cell surface antigen that is also a knownmarker of multipo-
tent stem cells in blood and other tissues, including the brain
(Galli et al., 2004; Singh et al., 2003; Yuan et al., 2004). The
CD133-positive cells isolated from human brain tumors can initi-
ate formation of ‘‘neurospheres’’ when cultured under nonadher-
ent conditions in medium supplemented with EGF and FGF.
When these growth factors are removed and the tumor neuro-
spheres are cultured under adherent conditions in serum-
supplemented medium (or, in some studies, LIF-supplemented
medium), individual cells began to express marker proteins as-
sociated with neurons and glia (Galli et al., 2004; Hemmati
et al., 2003; Ignatova et al., 2002; Singh et al., 2003). Notably,
the repertoire of neuronal and glial marker proteins that are ex-
pressed under these conditions recapitulates, the repertoire of
multipotent neural progenitors (Galli et al., 2004; Hemmati
et al., 2003; Singh et al., 2003).
Such CD133-positive, neurosphere-forming cancer stem cells
are typically a minor subset of the total cells within glioma. How-
ever, they are by far the most tumorigenic component of the tu-
mor. For example, disaggregated cells from fresh surgical iso-
lates of malignant glioma will form tumors when inoculated into
the cranium of immune suppressedmice; typically though, an in-
noculum of at least 105 cells is required to initiate tumor growth.
By contrast, as few as 100 CD133-positive cells will suffice to ini-
tiate tumor formation (Singh et al., 2004). Interestingly, in accord
with the cancer stem cell hypothesis, the CD133-positive glioma
stem cells are relatively resistant to radiation (Bao et al., 2006a).
Glioma Stem Cells: Caveats
There are exceptions to the stem cell properties noted above and
experimental pitfalls for the unwary. For example: (1) Not all of834 Neuron 58, June 26, 2008 ª2008 Elsevier Inc.the cells that fit the operational definition of a glioma stem cell
are marked by CD133. Some gliomas contain CD133-negative
cells that, in every other respect, fit the operational definition of
a cancer stem cell (Beier et al., 2007). (2) CD133 is expressed
on cells that are not glioma stem cells—for example, endothelial
cells. Slowly cycling endothelial cells are expected to be intrinsi-
cally resistant to radiation and could (in principle at least) com-
plicate the analysis of radiosensitivity studies such as those
conducted by Bao et al. (2006a). (3) Experiments with tumor xe-
nograft models may lead to underestimation of the percentage of
tumor-initiating or ‘‘tumor-sustaining’’ cells (Kelly et al., 2007). (4)
Some of the cellular heterogeneity seen in high-grade gliomas
may reflect the recruitment of nonmalignant neural or glial pre-
cursors into the tumor milieu (Assanah et al., 2006). These non-
malignant progenitors could contribute to the neurosphere pop-
ulation in vitro and obfuscate the interpretation of cell culture
experiments. (5) Single neurospheres are not usually derived
from single cells. Even in the absence of agitation or manipula-
tion, free-floating neurospheres are highly motile entities. Time-
lapse video microscopy shows that individual neurospheres
are rapidly drawn toward each other and merge to form larger
neurospheres, irrespective of whether cultures are passaged at
conventional density or very low density (Singec et al., 2006).
Neurosphere merger events are clearly germane to the property
of multiple fate choice—one of the defining characteristics of
a cancer stem cell.
Overshadowing all of these tactical concerns is a strategic
problem: Stem-like properties in a neoplastic cell cannot be
taken as evidence prima facie of a developmental origin from
a ‘‘stalled’’ neural progenitor. The cancer stem cell hypothesis
and the cellular origins of cancer are separate and distinct is-
sues. Graphic evidence of the disconnect between a stem-like
phenotype and a stem cell origin comes from studies on leuke-
mias where it has been shown that committed progenitor cells
can be transformed into leukemia stem cells by misexpression
of the oncogenic fusion protein MLL-AF9 (Krivtsov et al., 2006).
In the case of malignant glioma, there are at least three neural
cell types that could, in principle, serve as cell of origin for glioma
stem cells. These are (1) mature ‘‘dedifferentiated’’ glia, (2) ‘‘re-
stricted’’ neural progenitors that are normally unipotent, and (3)
multipotent neural progenitors (see Figure 5).
Cellular Progenitors of Glioma Stem Cells I:
The Case for Mature Glia
Prior to the discovery of replication-competent neural progeni-
tors in the postnatal brain (Reynolds and Weiss, 1992), mature
astrocytes or committed astrocyte progenitors were thought to
be the only replication-competent cells in the postnatal brain
and thus the only cells capable of malignant transformation.
The conceptual problem with mature or committed glia as tumor
progenitors is that the transformed glia would have to dedifferen-
tiate to produce the malignant, multipotent cells that are embed-
ded within human gliomas. This ‘‘retrograde differentiation’’
might seem counterintuitive; however, it has recently been
shown that genetic cocktails of just a few transcription factors
can convert normal skin cells into totipotent embryonic stem
cells (Nakagawa et al., 2008; Okita et al., 2007; Takahashi
et al., 2007; Wernig et al., 2007). Within this context, the
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tent neural progenitor seems to be a small and easily surmount-
able challenge.
Multiple studies have shown that early cortical astrocytes can
be targeted in vitro or in vivo with oncogenes or activated signal-
generating proteins to produce tumors in animal models with
convincing glioma histology (Bachoo et al., 2002; Blouw et al.,
2003; Ding et al., 2001; Holland et al., 1998a; Rich et al., 2001;
Sonoda et al., 2001; Uhrbom et al., 2005; Weiss et al., 2003;
Xiao et al., 2005). For example, Bachoo et al. (2002) isolated
neonatal astrocyte cultures from p16Ink4a/p19Arf null mice and
infected these cells with a retrovirus encoding a mutated,
constitutively active version of the EGF receptor (EGFRvIII). Neu-
rospheres generated from these genetically modified astrocytes
could form gliomas when implanted into the brains of SCID mice
(Maher et al., 2001). However, there are important caveats to
most of these studies.
Several lines of evidence suggest that in vitro and in vivo cel-
lular targeting paradigms select for a less mature cell in the as-
troglial lineage. First, retroviral expression vectors can only in-
fect proliferating cells and are thus biased toward immature
progenitors relative to their terminally differentiated progeny.
Second, such transformation-competent astrocyte cultures
can be generated from the neonatal cortex but not the adult
cortex, arguing for selection of a less mature astrocytic cell
type (Laywell et al., 2000). Indeed, culture of adult cortical as-
trocytes has proved extremely difficult. Third, cultured ‘‘astro-
cytes’’ are generally characterized by only one marker, GFAP,
which is found on multipotent precursors as well as reactive
astrocytes (see below). Finally, in vivo targeting studies suffer
from a lack of reliable and specific regulatory sequences to
drive gene expression specifically in mature cortical astrocytes.
In this regard, the commonly used marker GFAP is quite prob-
lematic because it is expressed in neural stem cells as well as
some committed astrocyte progenitors and cortical astrocytes
(Doetsch et al., 1999). Thus, a major remaining challenge for the
dedifferentiation hypotheses of glioma is the development of
genetic systems capable of selective transmission of oncogenic
events solely to mature astroglial cells. The critical need to dis-
cover novel markers of mature astrocytes was articulated in the
summary statement of the NINDS-sponsored ‘‘Workshop on
Astrocyte Function in Health and Disease (http://www.ninds.
nih.gov/news_and_events/astrocyte_function_health_disease.
htm).
Cellular Progenitors of Glioma Stem Cells II:
The Case for ‘Restricted’ Neural Progenitors
The discovery of replication-competent multipotent neural pro-
genitor cells in the postnatal brain (Reynolds and Weiss, 1992)
created an attractive alternative candidate for the glioma cell of
origin. Because such stem cells have the machinery for self-
renewal already activated, maintaining this activation may be
simpler then turning it on de novo in a more differentiated cell;
that is, fewer mutations might be required to maintain self-
renewal then to activate it ectopically (Reya et al., 2001).
‘‘Restricted progenitors’’ of the brain are able to proliferate but
are generally defined as unipotent. Examples include granule cell
neuron precursors of the cerebellum and oligodendrocyte pre-cursors in vivo. These restricted progenitors might first need to
acquire the self-renewal potential of multipotent progenitors to
have the opportunity to experience additional mutations that
would lead to transformation. Some insight into this process
can be taken from the hematopoietic system wherein restricted
lymphoid and myeloid progenitors fail to self-renew detectably
upon transplantation (Mikkola and Orkin, 2006; Tenen, 2003). In-
troduction of the MLL-AF9 fusion protein into committed granu-
locyte-macrophage precursors is sufficient for leukemic trans-
formation including generation of self-renewing stem cells
(Krivtsov et al., 2006).
Kondo and Raff have shown that committed oligodendroglial
progenitors can reacquire stem-like properties after extensive
treatment in vitro (Kondo and Raff, 2000), which results in chro-
matin remodeling and reactivation of the primitive neural epithe-
lial marker, Sox2 (Kondo and Raff, 2004). Interestingly, Sox2
expression is prevalent in human gliomas (Schmitz et al.,
2007), consistent with the possibility that similar mechanisms
could be involved in the process of transformation of a restricted
neural (glial) precursor to transformed cell type.
In the postnatal brain, cycling neural progenitors encompass
the diffuse NG2 progenitor cell population (Diers-Fenger et al.,
2001; Levine and Stallcup, 1987). NG2 cells are themost actively
cycling cells in the adult brain, and they have been reported
to have multipotent qualities (Belachew et al., 2003; Liu et al.,
2007). The majority of NG2 cells express Olig2, which is required
for oligodendrocyte lineage development (Ligon et al., 2006b),
consistent with the proposal that NG2 cells are fundamentally
similar to, or give rise to, oligodendrocyte precursors (Baracskay
et al., 2007). Others have argued that NG2 cells comprise a
distinct (fourth) neuroepithelial lineage (Greenwood and Butt,
2003; Nishiyama, 2007). In any case, NG2 cells can undergo
reprogramming in culture to produce neurons and astrocytes
via epigenetic mechanisms as described for oligodendrocyte
precursors (Liu et al., 2007). Fate mapping in vivo also supports
contributions to gray matter astrocytes (Zhu et al., 2008), al-
though it is unclear whether such NG2 cells with increased
potential represent a distinct functional subset or whether NG2
marks several classes of cells with distinct capabilities to form
astrocytes or oligodendrocytes (Tamura et al., 2007).
Cellular Progenitors of Glioma Stem Cells III:
The Case for Multipotent Neural Progenitors
Multipotent neural progenitors, found in specialized niches such
as the dentate gyrus and subventricular zone (SVZ), have been
extensively scrutinized, and have recently been suggested as
cells with potential to form gliomas (for reviews see Sanai
et al., 2005; Vescovi et al., 2006). Alvarez-Buylla and colleagues
have described several basic subclasses of SVZ progenitor cells
on the basis of histology and immunohistochemical and ultra-
structural characteristics (Alvarez-Buylla et al., 2001; Doetsch
et al., 1999). As indicated in Figure 2, quiescent ‘‘type B’’ stem
cells that expresses the astrocytic marker GFAP and exhibits
other morphological features of astrocytes are capable of re-
sponding to growth factors such as EGF and PDGF. Mitogen-
treated type B cells give rise to transit-amplifying type C cells
that in most cases will go on to form neuroblasts of the rostral mi-
gratory stream. However, type B cells can also give rise toNeuron 58, June 26, 2008 ª2008 Elsevier Inc. 835
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matter injury (Hack et al., 2005; Menn et al., 2006). Interestingly,
treatment with antimitotic agents such as cytosine-b-D-arabino-
furanoside destroys type C but not type B cells, a finding that
could be relevant for understanding the recurrence of brain can-
cer after chemo- and radiotherapy (Sanai et al., 2005).
As illustrated in Figure 2, these functional subgroups of the
normal SVZ provide a conceptual framework for investigating
features of gliomagenic stem cells as well as the cell of origin
for glioma. For example, the normal type B cell captures essen-
tial properties of quiescence, self-renewal, and multipotentcy
that one might ascribe to a cancer stem cell. Do glioma
stem cells arise from developmentally stalled neural progenitors
such as the type B cell? In the sections below, five separate
predictions of a neural progenitor cell of origin are put to the
test.
Prediction 1: Neural Progenitors and Brain Tumor Stem
Cells Are Driven by Common Signaling Pathways
Four examples of signal transduction pathways that modulate
growth and differentiation of neural progenitor cells during devel-
opment and also in the postnatal brain are depicted schemati-
cally in Figure 3. As indicated, mutations of key regulatory ele-
ments within these pathways are associated with adult gliomas
and pediatric medulloblastoma.
During development, Notch signaling promotes formation and
suppresses differentiation of radial glia (Gaiano et al., 2000). In
the postnatal brain, Notch promotes survival of neural progeni-
tors and thereby expands the population of these cells both in
vitro and in vivo (Androutsellis-Theotokis et al., 2006). The Notch
signaling pathway is constitutively active in many high-grade gli-
omas and glioma cell lines—conceivably through an autocrine/
juxtacrine loop mechanism involving coordinate expression of
Notch and Notch ligands (Purow et al., 2005). The activation
state of Notch in these tumors and tumor cell lines has lead to
Figure 2. Neural Progenitor Subtypes in the
Subventricular Zone
(Top) Coronal section through the postnatal adult
mouse forebrain depicts subventricular zone
(SVZ) progenitors in situ including type B (blue),
C (amber), and A (green) cells, as well as ciliated
ependymal cells (pink) that line the lateral ventricle
(see Alvarez-Buylla et al. [2001] for further read-
ing). (Bottom) Type B cells divide very slowly and
express the markers indicated. They give rise to
transient amplifying type C cells that in turn gener-
ate type A neuroblasts that contribute to the rostral
migratory stream in most cases. However, a frac-
tion of type C cells express Olig2 and NG2 and can
form myelinating oligodendrocytes. The potential
of type B cells to produce oligodendrocyte precur-
sors might relate in principle to tumor-compe-
tence for glioma.
the proposal that Notch pathway inhibi-
tors might be employed in glioma therapy
(Kanamori et al., 2007).
MitogenssuchasEGF, FGF,PDGF, and
LIF promote the growth of adult neural
progenitor cells from the subventricular
zone or dentate gyrus and are used routinely for neurosphere
cell culture (Jackson et al., 2006; Reynolds andWeiss, 1992; Shi-
mazaki et al., 2001; Vescovi et al., 1993). Amplification and/or ac-
tivating mutations in EGF and PDGF receptors are seen in adult
high-gradegliomas (Kesari et al., 2006).PDGF ligand/receptorau-
tocrine loopsarealsoacommon featureofmalignantgliomas inall
grade levels (Guha et al., 1995; Hermanson et al., 1992; Lokker
et al., 2002). The receptors for EGF, FGF, PDGF, and LIF all acti-
vate the canonical Ras/Raf/MAPK signaling axis (Weinberg,
2007). Loss-of-function mutations in NF1 (encoding a GTPase)
promote activation of the Ras/Raf/MAPK signaling axis and are
associated with low-grade astrocytomas in patients with heredi-
tary neurofibromatosis (Hochstrasser et al., 1988).
A parallel signaling pathway for growth factors and their
receptor tyrosine kinases involves the formation of phosphati-
dylinositol 3 phosphate via activation of phosphatidylinositol
3 kinase (PI3K). Activating mutations in this PI3K are etiologic
in a subset of high-grade gliomas (Samuels et al., 2004). The
trophic functions of PI3K on anabolic metabolism and survival
are opposed by the tumor-suppressor gene PTEN, which is
deleted in a high percentage of malignant gliomas (Duerr
et al., 1998; Furnari et al., 2007; Liu et al., 1997; Rasheed
et al., 1997).
Although they are less frequent than low-grade astrocytomas,
malignant medulloblastomas are actually the most common
malignant brain tumor of childhood (Grovas et al., 1997). Medul-
loblastomas are thought to originate from granule neuron precur-
sor cells in the external granular layer of the developing cerebel-
lum. Sonic hedgehog is a critical mitogen for these precursor
cells (Wechsler-Reya and Scott, 1999). Hereditary loss-of-func-
tion mutations in the Sonic hedgehog receptor Patched lead
to constitutive activation of the Sonic hedgehog pathway and
a predisposition to medulloblastoma in Gorlin syndrome (Bale
et al., 1998; Goodrich et al., 1997; Gorlin, 1987). Loss-of-function
mutations in ‘‘Suppressor of Fused’’ (SF) have been detected in836 Neuron 58, June 26, 2008 ª2008 Elsevier Inc.
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tations would likewise be expected to activate the Sonic hedge-
hog signaling axis (Figure 3).
What do these data say about the cancer stem cell hypothesis
and glioma cell of origin? As predicted by the hypothesis, CNS
cancer stem cells do appear to co-opt mitogenic cues that reg-
ulate the growth of normal neural progenitors. However, the
receptors for EGF, FGF, Shh, and Notch ligands are broadly ex-
pressed. In cell culture, EGF and FGF are known to promote the
growth of normal astrocytes derived from the neonatal cortex.
Thus, the outcome of prediction 1 is ambiguous with respect
to the cellular origins of CNS cancer stem cells.
Prediction 2: Signaling Pathways that Constrain
the Growth of Normal Progenitor Cells Are Suppressed
in Brain Cancers
Cell cycle progression of all mammalian cell types is governed by
the ‘‘RB signaling axis.’’ The central, cell-intrinsic features of this
signaling axis have been extensively reviewed (Adams and Kae-
lin, 1998; Gartel and Radhakrishnan, 2005; Pei and Xiong, 2005;
Sherr and Roberts, 1999). As indicated in Figure 4, there are
three key negative regulators in the RB signaling axis. All three
of the negative regulator elements in the RB signaling axis mod-
ulate the proliferation of neural progenitor cells.
Targeted disruption of p16INK4a has little effect on the anatomy
of the SVZ in young mice or on the replicative potential of SVZ
progenitor cells derived from young mice; however, deletion of
p16INK4a can partially oppose an age-related decline in the abun-
dance and self-renewal potential of SVZ neural progenitors (Mo-
lofsky et al., 2006). Targeted deletion of p21 opposes the relative
quiescence of neural progenitors in the adult forebrain, leading
to a transient surplus of these cells. This initial increase in the ab-
sence of p21 function is followed by a depletion and long-term
decrement in stem cell replicative potential. In aggregate, the
Figure 3. Common Mitogenic Cues for
Neural Progenitors and Brain Tumor Stem
Cells
Common gene amplifications, activating muta-
tions, or autocrine loops are indicated in red font.
Common deletions or loss-of-function mutations
are indicated in blue font. See text for details.
Note that the Hedgehog pathway is implicated
strongly in the cerebellar tumor, medulloblastoma,
whereas its roles in glioma are contended.
p21 null phenotype suggests that p21
contributes to the relative quiescence of
neural progenitors, which is necessary
for life-long maintenance of neural stem
cell self-renewal (Kippin et al., 2005).
Mice lacking p53 display an elevated
rate of cell proliferation in the adult SVZ.
This enhanced proliferation in vivo corre-
lates with an increase in the relative num-
ber of SVZ cells capable of forming neu-
rospheres in vitro and with an increased
number of stem cells within the neuro-
spheres that form (Meletis et al., 2006).
The Polycomb group gene silencer Bmi1 lies genetically up-
stream of the RB signaling axis and plays key roles in sustaining
the replication-competent state of normal neural progenitors. At
postnatal stages, knockout of Bmi1 dramatically reduces fore-
brain SVZ neural progenitors (Molofsky et al., 2003; Zencak
et al., 2005). As indicated in Figure 4, the postnatal requirement
for Bmi1 function is thought to reflect the repressive functions of
Bmi1 on the p16Ink4a/p19Arf gene products (Molofsky et al.,
2005). Targeted gene disruption reveals little or no requirement
of Bmi1 in the developing CNS. However, recent studies using
shRNA technology to achieve an acute knockdown of Bmi1
have shown a critical role for Bmi1 function for neural stem cell
self-renewal in the developing CNS. Surprisingly, the cell cycle
target for Bmi1 in the developing brain is not p16Ink4a/p19Arf
but rather p21 (Figure 4) (Fasano et al., 2007).
In addition to general regulators of the cell cycle, lineage-re-
stricted control mechanisms have recently been described.
The bHLH transcription factor Olig2 is expressed exclusively
within the central nervous system, where it contributes to the
cell cycle control of neural progenitors. During development,
Olig2 is expressed in progenitors that give rise to oligodendro-
cytes and certain neuronal subtypes, including motor neurons
in the developing spinal cord (Lu et al., 2002, 2000; Novitch
et al., 2001; Takebayashi et al., 2000; Zhou and Anderson,
2002; Zhou et al., 2000). In the adult CNS, Olig2 is expressed
in myelinating oligodendrocytes but is observed also in mito-
gen-treated ‘‘transit-amplifying cells’’ of the SVZ (Jackson
et al., 2006). Olig2 is also expressed in NG2-positive glia and re-
quired for the development of these cells (Ligon et al., 2006b).
Olig2 sustains the replication-competent state of neural progen-
itors (Lee et al., 2005b), perhaps in part through suppression of
p21 gene expression (Ligon et al., 2007).
Overlaps between the genes and gene products that regulate
stem cell proliferation and the genetic lesions that underlieNeuron 58, June 26, 2008 ª2008 Elsevier Inc. 837
Neuron
Reviewmalignant gliomas are readily apparent. The most common ge-
netic lesions found in primary high-grade gliomas consist of
loss-of-function mutations in the p16Ink4a and p19ARF negative
effectors of the RB signaling axis. However, RB itself is some-
times targeted. Gain-of-function mutations in the positive effec-
tor CDK4 are also observed (Figure 4) (Sauvageot et al., 2007).
The Bmi1 gene product is expressed in almost all human brain
tumors irrespective of grade. The expression of Bmi1 has been
shown to contribute to themalignancy of p16Ink4a/p19ARF double
null murine gliomas (Bruggeman et al., 2007). This observation is
superficially at odds with the known role of Bmi1 in repressing
the function of p16Ink4a/p19Arf (Molofsky et al., 2005). As indi-
cated in Figure 4, the p16Ink4a/p19ARF-independent function of
Bmi1 might reflect an epistatic relationship with Olig2 and p21
(Fasano et al., 2007). The Olig2 transcription factor is expressed
in 100%of adult astrocytomas, irrespective of grade (Ligon et al.,
2004). In adult gliomas, Olig2 expression marks essentially
100% of the CD133-positive putative glioma stem cells. Olig2
is also required for tumor formation in the same p16Ink4a/
p19ARF double null murine model of adult gliomas used by Brug-
Figure 4. Common Cell-Intrinsic Mechanisms Sustain Replication
Competence of Normal and Gliomagenic Neural Precursors
Generic components of the retinoblastoma (RB) cell cycle regulatory appara-
tus are shown. Negative regulators shown in blue are often deleted in malig-
nant glioma, while positive regulators shown in red are frequently amplified,
overexpressed, or mutated to a constitutively active state (reported frequen-
cies indicated to the right of each symbol) (Sauvageot et al., 2007). The Poly-
comb gene silencer Bmi1 is thought to be a critical regulator of p21 gene ex-
pression during development and of p16Ink4a/p19Arf expression in the
postnatal brain. The bHLH transcription factor Olig2 is expressed in essentially
100% of glioma stem cells (as defined by coexpression of CD133) and directly
suppresses expression of p21. See text for details.838 Neuron 58, June 26, 2008 ª2008 Elsevier Inc.geman et al. (2007). Finally, as noted above, Olig2 suppresses
the expression of p21 (Ligon et al., 2007).
What do these data say about the glioma cell of origin? Glioma
mutations found in general regulators of the cell cycle are equally
compatible with neural progenitors or mature astrocytes as tu-
mor cell of origin. However, Olig2 is not found in mature astro-
cytes (Lu et al., 2000; Takebayashi et al., 2000; Zhou et al.,
2000). The gliomagenic requirement for Olig2 (albeit in a mouse
tumormodel) provides a small edge in favor of neural progenitors
as cell of origin for glioma.
Prediction 3: Neural Progenitors Are Competent
for Transformation by Mutations Found in Human
Brain Tumors
‘‘Tumor competence’’ is a necessary feature of glioma progeni-
tor cells. The property of tumor competence in humans is pro-
vided by hereditary cancer syndromes such as Li-Fraumeni, ret-
inoblastoma, or familial breast cancer syndromes caused by
germline deletions of p53, RB, or BRCA, respectively. Patients
with these hereditary cancer syndromes develop a narrow spec-
trum of spontaneous tumors despite tissue-wide distribution of
the affected genes (Weinberg, 2007). Of particular relevance
to theCNS, germlinemutations of thePTCH gene, encoding a re-
pressor of the Hedgehog pathway (see Figure 3), give rise to
medulloblastoma in patients with Gorlin syndrome (Hahn et al.,
1996; Johnson et al., 1996). The fact that Gorlin syndrome pa-
tients—and also Ptch+/ mice (Goodrich et al., 1997)—typically
develop cerebellar tumors, but not forebrain glioma, indicates
a particular susceptibility of a subset of precursor cells in the
anterior posterior axis to respond to this particular oncogenic
pathway.
There are several strategies to define progenitor compart-
ments that are ‘‘competent’’ to produce tumors in vivo. Because
the many studies employing this strategy in brain cancer re-
search have been comprehensively reviewed (Furnari et al.,
2007), we will confine our own discussion to a few illustrative
cases. For example, expression of V(12) Ha-ras under control
of GFAP regulatory sequences directs activated Ras signaling
to this cellular compartment, yielding molecular insight into gli-
oma formation and a highly penetrant model (Ding et al., 2001;
Shannon et al., 2005).
Oncogenic rodent ecotropic retroviruses have provided useful
insights into gliomagenesis (Assanah et al., 2006), but this
approach targets a relatively broad range of proliferating cells
including multipotent and restricted progenitors. Other viral sys-
tems select for certain classes of precursor cells. For example
the adeno-associated virus serotype 5 (AAV5) utilizes PDGF
receptors for initial entry into the host cell (Di Pasquale et al.,
2003; Lotery et al., 2003). AAV5 expression vectors have been
used to fate map the progeny of PDGF receptor-positive type
B progenitor cells in the SVZ (see Figure 2) (Jackson et al.,
2006); however, a potential complication in this experiment is
that PDGFRa is also expressed on NG2 cells and oligodendro-
cyte precursors that are also present in the SVZ might also
be targeted.
Holland and Varmus developed a more flexible means of tar-
geting replication-competent avian sarcoma (‘‘RCAS’’) virus
expression vectors to specific cellular subcompartments in the
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sequences of interest to drive expression of TVA, the cell surface
receptor for ALV avian retrovirus (Holland et al., 1998a; Holland
and Varmus, 1998). Subsequent infection with avian sarcoma vi-
rus expression vectors in such transgenic mice is possible only
in TVA-positive cells. This RCAS system has been used to intro-
duce oncogenes (e.g., Ras), cell cycle regulatory factors (e.g.,
CDK4), growth factors (FGF, PDGF), growth factor receptor mu-
tants (e.g., activated EGFRvIII), and signal-generating proteins
(e.g., Akt) into subsets of nestin- or GFAP-expressing cells with
additional temporal-spatial control conferred by infection (Dai
et al., 2001; Holland et al., 2000, 1998a, 1998b; Holland and Var-
mus, 1998; Holmen and Williams, 2005; Tchougounova et al.,
2007). The RCAS, GFAP-tva system has also been used to target
type B adult neural stem cell populations (Figure 2) in fate-
mapping studies (Menn et al., 2006) and has provided a means
to introduce oncogenic events into this subclass of neural
stem cells, which are implicated in gliomagenesis based on other
studies. Despite its intrinsic flexibility as a platform for glioma
modeling, the RCAS system is ultimately limited by reliability
and specificity of the regulatory sequences to drive TVA gene
expression in the rodent brain. Based on drawbacks discussed
above regarding the available GFAP and Nestin promoters,
new TVA-based transgenics based on regulatory elements
from lineage- and/or stage-specific markers of stem cells and
glial subtype developmental programs could provide important
new tools for gliomagenic studies.
Parada and his associates have developed a true in vivo
genetic model for malignant glioma that nicely illustrates the
phenomenon of tumor competence. In this model, GFAP-cre
recombinase transgenic mice are used to achieve targeted dele-
tion of a floxed Nf1 tumor suppressor gene in a p53 null back-
ground. The underlying genetic lesions for the tumors that arise
in this model system are present from the onset in allGFAP-pos-
itive cells of the brain, including SVZ progenitors and the more
mature astroglial cells of cortical white matter. Nevertheless
the majority of the tumors that arise in this system at early times
appear to originate from the SVZ (Zhu et al., 2005) wherein reside
the GFAP-positive type B neural progenitor cells (Doetsch et al.,
1999). As a whole, the phenomenon of tumor competence
makes a rather compelling argument for neural progenitor cells
as cell of origin for malignant gliomas. Multiple murine models
show that neural progenitors are susceptible to malignant trans-
formation by genetic lesions found in human tumors. By con-
trast, other cell types bearing identical lesions in vivo are not
transformed.
It should be noted that none of the animal studies show that
malignant gliomas arise directly frommultipotent neural progen-
itors. In the genetic model described by Zhu et al. (2005) for ex-
ample, all descendants of the GFAP-positive multipotent B cells
will be genetically equivalent. The ultimate list of genetic equiva-
lents includes type D transit-amplifying cells, someNG2-positive
glia, and some oligodendrocyte progenitors (see Figure 2). Oli-
godendrocyte progenitors and NG2-positive glia are capable
of migrating extensive distances away from the SVZ, and yet
themajority of tumors arise initially within the SVZ. The spatial re-
striction could mean that only B cells and/or transit-amplifying
D cells are competent for malignant transformation. However,there is an alternative explanation. One principle weakness in
the competence argument is the question of cell autonomy.
It could be argued for example that mature astrocytes in the
model of Zhu et al. (2005) actually are competent for malignant
transformation, but their malignant potential is not displayed be-
cause the cells are not positioned within a permissive ‘‘mitogenic
niche.’’ As has been noted, mature astrocytes or astrocyte pro-
genitors are competent for malignant transformation when onco-
genic mutations are introduced in vitro under conditions permis-
sive for growth (Bachoo et al., 2002; Bruggeman et al., 2007).
Although it is beyond the scope of this review, considerable
attention is now being focused on symbiotic relationships be-
tween neural stem cells, glioma stem cells, and the blood vascu-
lar system (Bao et al., 2006b; Calabrese et al., 2007; Shen et al.,
2004; Yang andWechsler-Reya, 2007). Disruption of the support
system afforded by the mitogenic niche might be a viable thera-
peutic strategy.
Prediction 4: Brain Tumors Will Initiate and/or Cluster
near the Germinal Centers of the Brain
If gliomas are derived from multipotent type B cells of the SVZ
in humans, then brain cancers might be expected to cluster
within or near this germinal region, at least at the time of incep-
tion (Figure 2). If gliomas arise from committed astrocytes or
NG2 cells, a more diffuse distribution of tumors might be ex-
pected. As indicated in Figure 5, the raw clinical data are actually
more consistent with astrocytes or NG2-positive glia as tumor
cells of origin. At the time of diagnosis, malignant gliomas are
typically imaged within the brain parenchyma at a distance
from the SVZ in subcortical white matter, along blood vessels
and in subpial collections. However, malignant gliomas prolifer-
ate rapidly and alsomigrate rapidly along white matter tracts and
throughout all layers of the brain. Thus, at later stages of glioma
development, when patients become symptomatic from the
mass effect of a large tumor, the initial anatomical ties to the
SVZ might be obscured.
This hypothetical scenario is gaining support from several lines
of evidence. In the GFAP-cre, floxed Nf1, p53/ astrocytoma
model (described above), gliomas arise with high penetrance
and at predictable times (Zhu et al., 2005). Accordingly, the tu-
mors can be tracked from their onset by cranial MRI and by im-
munohistochemical analysis of brains from animals euthanized
at sequential stages of development. These data show that the
SVZ is the site where gliomas first develop. At early times, focal
zones of hyperplasia are noted in the SVZ of affected mice. At
later times, thin streams ofmitotic cells are observed along tracts
of white matter leading to the cortex. Ultimately, these migratory
stalks are obscured. The trophic and/or chemotactic factors that
regulate migration of glioma progenitors in this model, as well as
human glioma, are unclear. In this respect, it is interesting to con-
sider that EGFR overexpression, found commonly in human
glioma, is sufficient to confer migratory properties to neural pro-
genitors (Aguirre et al., 2005). Similarly, SVZ c-cells are EGF re-
sponsive and respondwithmass-like proliferations, highmotility,
and migration along white matter tracts and blood vessels
(Doetsch et al., 2002). Other studies suggest that PTEN and
HIF signaling in tumor cells and stroma, respectively, alsoNeuron 58, June 26, 2008 ª2008 Elsevier Inc. 839
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(Top) The embryonic CNS is patterned by organizing signals (e.g., Sonic hedgehog [Shh]) and activity of homeodomain and bHLH transcription factors into dis-
crete domains of progenitor cells in the anterior-posterior and dorsal-ventral axes. Such pattering could relate to ultimate heterogeneity and tumor competence of
subsets of persistent neural progenitors in the adult brain. Shown at left are prosomere and rhombomere boundaries of the embryonic brain. At right, restricted
domains of neuronal and glial progeny subtype production suggested by recent work are indicated. (Bottom) If gliomas are derived frommultipotent type B cells
of the SVZ in humans, then brain cancers might be expected to cluster within or near this germinal region, at least at the time of inception. Subsequently, they
could migrate to the cerebrum. Alternatively, gliomas might arise from committed astrocytes or NG2 cells. See text for details.dramatically regulate tumor cell migration (Blouw et al., 2003;
Xiao et al., 2005).
As previously mentioned, because human gliomas usually
present at a late stage, and due to the relatively low resolution
of current imaging modalities, it has not been possible to serially
track tumor progression from progenitors of the SVZ. In recent
work, the spatial relationship of the contrast-enhancing gliomas
to the SVZ was examined, revealing a significant subset of tu-
mors that either contacted or were located with proximity to
the SVZ (Lim et al., 2007). Thus, the possibility that human glioma
could arise from fundamentally similar cells as those resident in
the SVZ remains open and is a compelling area for further re-
search (Sanai et al., 2005; Vescovi et al., 2006). In summary,
the weight of the imaging data from mouse models and a recent
clinical study are modestly supportive of the hypothesis that
adult neural progenitors in the SVZ serve as cell of origin for gli-
oma stem cells. However, if brain cancers indeed arise in the
SVZ, one must assume that the tumorigenic precursors migrate
rather rapidly to more favorable ‘‘mitogenic niches’’ of the brain
for tumor expansion before clinical symptoms arise.840 Neuron 58, June 26, 2008 ª2008 Elsevier Inc.Prediction 5: Genes that Govern Replication
Competence of Neural Progenitors Will Serve
as ‘Gatekeepers’ for Development of CNS Cancers
A final prediction of the cancer stem cell hypothesis is that similar
lineage-restricted genetic requirements for development and
survival of stem cells during organogenesis will apply to cognate
primary cancers (Garraway and Sellers, 2006). For example, the
transcription factorMITF is required both for normal melanoblast
development and generation of melanoma (McGill et al., 2002).
Common genetic requirements for tissue development and
tumor formation support the proposition that proliferation and
survival of tumor cells may be dependent on the same ‘‘gate-
keeper’’ pathways that govern early phases of organogenesis.
In principle, these tissue-type-specific gatekeeper functions
could be targeted for cancer therapy with the benefit that ‘‘off
target’’ collateral damage to other organs would be limited.
In the CNS, OLIG2 might be considered an example of one
such gatekeeper for malignant stem cells in glioma because
it regulates two cardinal features of stem cells: multipotency
and self-renewal. The archetypal hematopoietic stem cell can
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mental conditions. In the CNS, neurospheres capable of gener-
ating neurons, astrocytes, and oligodendrocytes can be cultured
from certain parts of the brain in the presence of mitogens such
as FGF and/or EGF. The mitogen-induced expansion of these
multipotent neurospheres seems to select for cells that express
Olig2 (Ligon et al., 2007). Olig2 function, moreover, is necessary
to regulate the full potential of such cells to produce all three neu-
ral lineages: neurons, astrocytes, and oligodendrocytes (Zhou
and Anderson, 2002). Pathological overtones of the link between
Olig gene function and cell proliferation are found in human
astrocytomas, wherein 85% of all proliferating cells and virtually
100% of all CD133-positive cells are positive for Olig2 expres-
sion. In ‘‘genetically relevant’’ p16Ink4a/p19Arf null, EGFRVIII-pos-
itive tumor neurospheres, a model of WHO grade III astrocytoma
(Bachoo et al., 2002), Olig2 function is necessary for tumorigen-
esis (Ligon et al., 2007).
In summary, there is a common genetic requirement for repli-
cation competence in a subset of neural progenitors and for
tumor formation in amurinemodel of primary glioma. This obser-
vation supports the cancer stem cell hypothesis and cannot be
reconciled with committed astrocyte progenitors or their prog-
eny as cell of origin for glioma. Further work is needed to deter-
mine whether these observations are relevant to the biology of
other forms of CNS cancer in adults and children and, in partic-
ular, whether gliomaswith other oncogenic mutations than those
tested above also require OLIG2 function.
Cancer Stem Cells and the Cell of Origin for Malignant
Glioma: Reprise
Malignant cells with stem-like properties have been found in
a wide range of adult and pediatric brain cancers. Do these can-
cer stem cells arise from developmentally arrested progenitor
cells that drive normal brain development and tissue repair?
Five testable predictions of this hypothesis are more or less sup-
ported by the literature reviewed here. However, in the words of
Enrico Fermi, ‘‘Experimental confirmation of a prediction is
merely a measurement. An experiment disproving a prediction
is a discovery.’’ We have noted ambiguities, loopholes, gray
areas in the data, and additional work to be done for each of
the predictions tested here. Committed progenitors for blood
or brain can clearly acquire stem-like properties when trans-
formed in vitro (Bachoo et al., 2002; Krivtsov et al., 2006). A ret-
rograde, somatic-to-stem cell path may be an occasional or
even a frequent route to the neoplastic state for some types of
brain cancer. It is only Ockham’s razor, applied to the data in
toto, that currently favors a multipotent stem cell origin for malig-
nant glioma.
In accord with the subjective state of the field, terms such as
‘‘tumor-initiating cells’’ or ‘‘tumor-propagating cells’’ are some-
times substituted for ‘‘cancer stem cells’’ because the later
term implies unwarranted insight into the tumor cell of origin
(Hill and Perris, 2007; Kelly et al., 2007). We agree that the
‘‘stem cell’’ descriptor is somewhat prejudicial. However, for
CNS tumors, the cancer stem cell hypothesis has thus far pro-
vided (1) a template for experimental design and (2) an incentive
for neuro-oncologists to think about fundamental problems in
brain development. Going forward, we believe that the benefitsof terms such as ‘‘cancer stem cell’’ or ‘‘glioma stem cell’’ as
consciousness-raising devices justify some modest conces-
sions to semantic rigor.
The Road Ahead
Prominent milestones in the cancer stem cell hypothesis and
glioma stem cells are summarized in Table 1. Note the pivotal
role of hematology and the hematologic malignancies in devel-
opment of the cancer stem cell paradigm. However, analogies
between cancers of the blood and cancers of the brain can
only be taken so far. Further progress may come at the points
where development of blood and brain diverge.
Unlike hematopoiesis, CNS development proceeds in precise
relation to position in the dorsal-ventral and anterior-posterior
axes (Kiecker and Lumsden, 2005; Tanabe and Jessell, 1996)
(Figure 5). For example, bHLH and homeodomain proteins ex-
pressed in spatially restricted domains of the ventral neural
tube and forebrain have been shown to govern oligodendrocyte
and astrocyte subtype specification (Hochstim et al., 2008; Lu
et al., 2002; Muroyama et al., 2005; Petryniak et al., 2007;
Zhou and Anderson, 2002). Recent studies show that progenitor
zoneswithin the adult SVZ are likewise spatially diversified. Stem
cells that are separated from each other by distances of far less
than a millimeter can have very different fates (De Marchis et al.,
2007; Merkle et al., 2007; Young et al., 2007). Differences in pro-
genitor pools within the anterior-posterior axis of the CNS (Klein
et al., 2005; Lee et al., 2005a) might also be reflected in the
molecular phenotype or behavior of gliomas (Sharma et al.,
2007). In future years, a precise characterization of progenitor
cell subtypes with specific markers may shed light on new tu-
mor-competent subsets in the postnatal brain.
Neural progenitors also obey temporal restrictions that deter-
mine their ability to produce neurons or glia during development
(Anderson et al., 2001; Edlund and Jessell, 1999; Ligon et al.,
2006a; Liu and Rao, 2004). With respect to human glioma, tem-
poral restriction on progenitor cells is probably best exemplified
by dramatic differences observed in the location and underlying
mutations observed in pediatric versus adult glioma. Adult glio-
mas are typically found in the supratentorial region and are char-
acterized by mutation of PTEN, INK4A/ARF, P53, and activation
or upregulation of EGFR expression (Figures 3 and 4). In con-
trast, pediatric astrocytomas are prominently found in infratento-
rial locations such as the brainstem. Few of the genetic lesions
associated with adult gliomas (e.g., PTEN mutation and EGFR
amplification) have been found in pediatric gliomas (Biegel and
Pollack, 2004; Pollack et al., 1997, 2006; Ullrich and Pomeroy,
2006). The time of onset, location, and different genetic proper-
ties of pediatric and adult glial tumors suggest different modes
of tumorigenesis.
Overshadowing all of these academic concerns is the issue of
targeted therapy. All of the mutations currently associated with
malignant glioma lie in genes and signaling pathways that are
broadly expressed and generally required for cell growth and
survival (Figures 4 and 5). In principle (if not quite in practice),
small molecule inhibitors of growth factor receptors such as
EGFR and intracellular signal-generating proteins such as PI3 ki-
nase are nomore selective for brain cancer cells than radiation or
conventional chemotherapeutic drugs. If cancer genetics cannotNeuron 58, June 26, 2008 ª2008 Elsevier Inc. 841
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of development biology and cancer cell biology?
Already, monoclonal antibodies to a drug export protein found
in progenitor cell subsets of normal skin have been shown to
have therapeutic value against human melanoma stem cells (or
melanoma-initiating cells) in mouse xenograft models (Schatton
et al., 2008). Other potential drug targets may be embedded in
transcription factors that direct the fate choice decisions of un-
committed progenitor cells. As noted above (‘‘Prediction 5’’),
the MITF and Olig2 transcription factors, required for develop-
ment of normal melanoblasts andCNS progenitors, respectively,
serve also as ‘‘gatekeeper’’ genes for malignant melanoma and
malignant glioma. Transcription factors are currently regarded
as suboptimal targets for drug development. However, some
transcription factor functions can be opposed at posttransla-
tional levels, and new chemical technologies may enable direct
inhibition of critical protein-protein interactions (Bernal et al.,
2007; Walensky et al., 2004).
These practical overtones of the cancer stem cell hypothesis
cannot come soon enough. A new generation of targeted thera-
peutics would be a boon to growing children with low grade as-
trocytomas who are currently being treated with radiation and
cytotoxic drugs. For adults with malignant glioma, the need is
for effective therapies of any sort. The median interval from diag-
nosis to death for adult patients with glioblastoma multiforme is
currently only 14 months.
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